Use access key #2 to skip to page content.
$0.30 0.06 (25.00%)
10/13/2008 11:56 AM

MDRNA, Inc. (MRNA)

CAPS Rating:
**

A pharmaceutical company, which is focusing on development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology for delivering both small and large molecule drugs.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

MRNA doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

124 Outperforms
16 Underperforms
 

All-Stars

14 Outperforms
6 Underperforms
 

Wall Street

3 Outperforms
0 Underperforms
 

Members bullish on MRNA are also bullish on:

Members bearish on MRNA are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (295)
Suggest a tag

MDRNA, Inc. At A Glance

Current Price: $0.30
Last Trade Time: 10/13/2008 11:56 AM
Open: $0.24
Previous Close: $0.24
Daily Range: $0.23 - $0.30
52-Week Range: $0.22 - $1.35
Volume: 49,153
Market Cap: $7.50M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

MRNA VS S&P 500 (SPY)

MRNA 12 month chart vs. S&P

News & Discussion Boards

Sorry no news articles available for MRNA.

Top Bull Pitch

Recs

2

MDRNA, Inc. (MRNA)

Avatar blaster888 (83.72) Submitted: 12/12/06 9:45 PM

Large pipeline of drugs, deal with PG, cash on hand and no debt. Novel delivery system. Potentially huge patent covering analogs of Peptide YY, or peptide derivatives, in the fields of obesity, so that anyone that makes a deal using PYY will have to pay NSTK for it's use.

Replies: 3 | Reply | Permalink

Top Bear Pitch

Recs

2

MDRNA, Inc. (MRNA)

Avatar DrQuay (95.29) Submitted: 9/28/07 9:04 AM

9/28/07 Ingredients for Failure!
1)Past record and continued loses makes statistics dismal.
2)After 32 Touts & Video's by Jim Cramer all year, he has now stated on his show 9/26 That Nstk is Don't Buy and wait until it's around $12 dollars.
3) Areas of Osteoporosis, Diabetes, and RNAI...More

Replies: 7 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 30 :   1 2 3 4 5 Next »

Show Pitch Replies

Recs

0

 (MRNA)

Avatar CoffeeInBed101 (99.79) Submitted: 10/03/08 4:16 PM : Outperform Start Price: $14.11 MRNA Score: -61.98

The longer I hold this dog, the lower the S&P gets to erase some of those points. Burn baby, burn.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MRNA)

Avatar JDSancho (95.10) Submitted: 6/18/08 9:26 PM : Underperform Start Price: $6.29 MRNA Score: 61.12

This Minyanville article sums up my feelings on MDRNA...I mean...Nastech...no, I was right, MDRwhocares.

http://www.minyanville.com/articles/MRK-amgn-IMCL-CTIC-ALNY-MRNA/index/a/17562/from/yahoo

This company plays perfectly into my "underperform due to sudden name change but not sudden better business outlook" theory. Truth be told, I did not read the whole article for I find biotech information rather boring and completely un-understandable. But, I read enough to make an underperform call here...said company lacks patents (and cash for that matter, only $20M left). I know enough to understand that patents (and cash) are everything in this field. When MDRNA secures a patent, it will be time to bail on this red thumb, but that doesn't look likely, at least any time soon. Plus, they have all kinds of management problems, which usually does not lead to a higher stock price. Therefore, I'll wait for my bankruptcy charm.

Report this Post Replies: 2 | Reply | Permalink

Recs

0

 (MRNA)

Avatar MyMacFool (< 20) Submitted: 11/14/07 2:47 PM : Underperform Start Price: $5.78 MRNA Score: 59.26

GREAT IDEAS CRAPPY PERFORMANCE

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MRNA)

Avatar pgueudet (< 20) Submitted: 11/09/07 10:52 AM : Underperform Start Price: $6.35 MRNA Score: 60.95

No product on the market, No partner

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MRNA)

Avatar jpmkorea (< 20) Submitted: 11/07/07 11:37 AM : Outperform Start Price: $8.91 MRNA Score: -60.17

Contrarian strategy to the max. Buy Low, Sell High. Oh Yeah!

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 30 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 3 of 3  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJimCramer 82.29 03/16/07 Outperform 3W $9.81-97.15%-31.27%-65.87
TrackWedbush 46.16 12/14/06 Outperform NS $16.25-98.28%-32.88%-65.39
TrackNeedham < 20 11/20/06 Outperform NS $19.21-98.54%-32.03%-66.51

Results 1 - 3 of 3  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners